uniQure N.V. (QURE) NASDAQ
26.46
-0.54(-2.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
26.46
-0.54(-2.00%)
Currency In USD
| Previous Close | 27 |
| Open | 27.33 |
| Day High | 27.5 |
| Day Low | 25.65 |
| 52-Week High | 71.5 |
| 52-Week Low | 8.73 |
| Volume | 1.16M |
| Average Volume | 1.89M |
| Market Cap | 1.67B |
| PE | -7.58 |
| EPS | -3.49 |
| Moving Average 50 Days | 21.59 |
| Moving Average 200 Days | 26.89 |
| Change | -0.54 |
uniQure to Announce 2025 Financial Results
GlobeNewswire Inc.
Feb 23, 2026 12:05 PM GMT
~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
GlobeNewswire Inc.
Feb 06, 2026 12:05 PM GMT
~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~
uniQure Announces Type A Meeting Scheduled with FDA
GlobeNewswire Inc.
Jan 09, 2026 12:05 PM GMT
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S.